Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity
Tóm tắt
Marginal structural models are causal models designed to adjust for time-dependent confounders in observational studies with dynamically adjusted treatments. They are robust tools to assess causality in complex longitudinal data. In this paper, a marginal structural model is proposed with an innovative dose-delay joint-exposure model for Inverse-Probability-of-Treatment Weighted estimation of the causal effect of alterations to the therapy intensity. The model is motivated by a precise clinical question concerning the possibility of reducing dosages in a regimen. It is applied to data from a randomised trial of chemotherapy in osteosarcoma, an aggressive primary bone-tumour. Chemotherapy data are complex because their longitudinal nature encompasses many clinical details like composition and organisation of multi-drug regimens, or dynamical therapy adjustments. This manuscript focuses on the clinical dynamical process of adjusting the therapy according to the patient’s toxicity history, and the causal effect on the outcome of interest of such therapy modifications. Depending on patients’ toxicity levels, variations to therapy intensity may be achieved by physicians through the allocation of either a reduction or a delay of the next planned dose. Thus, a negative feedback is present between exposure to cytotoxic agents and toxicity levels, which acts as time-dependent confounders. The construction of the model is illustrated highlighting the high complexity and entanglement of chemotherapy data. Built to address dosage reductions, the model also shows that delays in therapy administration should be avoided. The last aspect makes sense from the cytological point of view, but it is seldom addressed in the literature.
Từ khóa
Tài liệu tham khảo
Robins JM. Marginal structural models. In: Proceedings of the American Statistical Association, Section on Bayesian Statistical Science, Anaheim, CA, 1997; 1–10. ISBN: 1883276535.
Klein JP, Van Houwelingen HC, Ibrahim JG et al. Handbook of survival analysis. Boca Raton, FL: CRC Press, 2013.
Almirall D, Coffman CJ, Yancy Jr WS, et al. Structural nested models. In: Analysis of observational health care data using SAS. SAS Institute, 2010.
Lok JJ. Statistical modelling of causal effects in time. PhD Thesis, Leiden University, 2001.
Robins JM. Structural nested failure time models. In: Survival Analysis, Andersen PK, Keiding N (Eds.), The Encyclopedia of Biostatistics, Armitage P, Colton T (Editors). Chichester, UK: Jophn Wiley and Sons, 1998. pp 4372-4389.
Robins JM. Marginal Structural Models versus Structural nested Models as Tools for Causal inference. In: Halloran ME, Berry D. (eds) Statistical Models in Epidemiology, the Environment, and Clinical Trials. The IMA Volumes in Mathematics and its Applications, vol 116. Springer, New York, NY, 2000, pp. 95-133.
Banack HR, 2016, Am J Epidemiol, 183, 122
Pazdur R, Wagman LD, Camphausen KA, et al. Cancer management: a multidisciplinary approach: medical, surgical & radiation oncology. New York, NY: Oncology Group, 2003.
Dear RF, 2013, Cochrane DB Syst Rev, 12
US Dept of Health and Human Services. Common terminology criteria Common Terminology Criteria for Adverse Events (CTCAE) 2010, https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed 1 June 2018).
Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65–74.
Bielack SS, Smeland S, Whelan J, et al. MAP plus maintenance pegylated interferon {α}-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 “good response” randomization. J Clin Oncol 2013; 31(supp 18): LBA10504–LBA10504.
EURAMOS. A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to a randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy, http://www.euramos.org/media/1258/euramos1_protocol.pdf (accessed 1 June 2018).
Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: the euramos experience. In: Jaffe N, Bruland O and Bielack S (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA.
Robins JM and Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G and Molenberghs G (eds) Longitudinal Data Analysis, Chapter 23. Chapman & Hall/CRC, 2009, pp. 553–599.
van der Wal WM, 2011, J Stat Softw, 43, 1